January 8, 2021
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) remained the top-selling drug in Japan in 2020 for two years running with sales of 119.6 billion yen on an NHI price basis, according to a Jiho tally based on the monthly snapshot reports issued...read more